European CHMP recommends paediatric license extension of adalimumab (Humira) for moderately to severely active ulcerative colitis

The license extension is for treatment of ulcerative colitis in patients from 6 years of age who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications.

Source:

European Medicines Agency